74830-47-0

Upstream product

• 934-28-1 bicyclo(2.2.1)heptane-2-endo-carboxylic acid 
• 934-29-2 acide bicyclo<2.2.1>heptane carboxylique-2 exo 
• 2534-71-6 (+/-)-2-bromo-norbornane-2endo-carboxylic acid 
• 934-28-1 norbornane-2-carboxylic acid 
• 18720-30-4 norbornane-1-carboxylic acid 
• 3574-54-7 2-endo-Bicyclo<2.2.1>heptanecarboxaldehyde 
• 19926-90-0 (+/-)-endo-bicyclo[2.2.1]hept-5-ene-2-carbaldehyde 
• 1755-01-7 endo-Dicyclopentadien 
• 61242-71-5 (1R,2S,4S)-Bicyclo[2.2.1]heptane-2-carboxylic acid ethyl ester 
• 51789-95-8 bicyclo[2.2.1]hept-5-ene-endo-2-carboxylic acid ethyl ester 
• 100379-07-5 2-exo-Bromobicyclo<2.2.1>heptane-2-endo-carboxaldehyde 

Downstream Products

• 41248-20-8 (+/-)-2-hydroxy-norbornane-2endo-carboxylic acid 
• 104085-12-3 (1S,2S,4R)-2-Bromo-bicyclo[2.2.1]heptane-1-carboxylic acid ((R)-2-hydroxy-1-phenyl-ethyl)-amide 
• 104085-11-2 (1R,2R,4S)-2-Bromo-bicyclo[2.2.1]heptane-1-carboxylic acid ((R)-2-hydroxy-1-phenyl-ethyl)-amide 
• 104085-14-5 (R)-2-((1S,2S,4R)-2-Bromo-bicyclo[2.2.1]hept-1-yl)-4-phenyl-4,5-dihydro-oxazole 
• 104085-13-4 (R)-2-((1R,2R,4S)-2-Bromo-bicyclo[2.2.1]hept-1-yl)-4-phenyl-4,5-dihydro-oxazole 
• 104085-15-6 (1R,2R,4S)-2-Bromo-bicyclo[2.2.1]heptane-1-carboxylic acid (R)-2-amino-2-phenyl-ethyl ester 
• 104085-16-7 (1S,2S,4R)-2-Bromo-bicyclo[2.2.1]heptane-1-carboxylic acid (R)-2-amino-2-phenyl-ethyl ester 
• 2287-57-2 methyl bicyclo<2.2.1>heptane-1-carboxylate 
• 18720-30-4 norbornane-1-carboxylic acid 
• 699-55-8 bicyclo[2.2.2]octane-1-carboxylic acid 
• 2574-42-7 bicyclo<2.2.2>octane-1-methanol 
• 7363-97-5 bicyclo<2.2.2>octane-1-carboxaldehyde tosylhydrazone 
• 149891-94-1 bicyclo<2.2.2>octane-1-carboxaldehyde-d tosylhydrazone 
• 2534-77-2 exo-2-bromonorbornane 

Relevant academic research and scientific papers

CARBOCYCLIC PROLINAMIDE DERIVATIVES

This invention is directed to novel carbocyclic prolinamide derivatives of Formula (I), and pharmaceutically acceptable salts, solvates, solvates of the salt and prodrugs thereof, useful in the prevention (e.g., delaying the onset of or reducing the risk

Protected amino hydroxy adamantane carboxylic acid and process for its preparation

Dipeptidyl peptidase IV (DP 4) inhibiting compounds are provided. The provided compounds can be used for treating diabetes and related diseases, especially Type II diabetes, and other diseases as set out herein, employing such DP 4 inhibitor or a combination of such DP 4 inhibitor and one or more of another antidiabetic agent such as metformin, glyburide, troglitazone, pioglitazone, rosiglitazone and/or insulin and/or one or more of a hypolipidemic agent and/or anti-obesity agent and/or other therapeutic agent.

From norbornane-based nucleotide analogs locked in South conformation to novel inhibitors of feline herpes virus

A synthetic route toward a series of unique cyclic nucleoside phosphonates locked in South conformation is described. The desired conformation is stabilized by a substitution of the sugar moiety by bicyclo[2.2.1]heptane (norbornane) bearing a purine or pyrimidine nucleobase in the bridgehead position. Although the final phosphonate derivatives are devoid of any significant antiviral activity probably due to the unfavorable conformational properties, several intermediates and their analogs exhibit surprising activity against feline herpes virus. Since these compounds do not possess an appropriate hydroxymethyl function allowing phosphorylation and subsequent incorporation into the polynucleotide chain, it seems to be likely that these compounds act by a novel unknown mechanism of action and may represent a new possible alternative for nucleoside and nucleotide therapeutics of this widely spread feline infection. A number of derivatives exerted also a significant antiviral activity against Coxsackievirus B3 and B4.

Bicyclonon-1-ene: Matrix Isolation and Spectroscopic Characterization of a Moderately Strained Bridgehead Olefin

Bicyclonon-1-ene was generated in low-temperature matrices and in fluid solutions by photodecomposition of bicyclooct-1-yldiazomethane and its photorearrangement product, 3-(bicyclooct-1-yl)diazirine.It was characterized by IR and UV absorption and by 1H and 13C NMR spectroscopy.Further evidence for the proposed structure was provided by self-trapping and by the spectral effects of deuteration on the olefinic carbon.Observed IR spectra and isotopic shifts agree well with the results of semiempirical (MNDO) and ab initio (SCF/6-31G*) calculations.

cis-Diazenes. Viscosity Effects, One-Bond Scission, and Cis-Trans Isomerization

Effects of solvent viscosity on the rates of overall thermal decomposition, deazatization, and iomerization of several symmetric and unsymmetric cis-diazenes (cis-azoalkanes) have been determined in pure alkanes and mixtures of octane and mineral oil.Increasing viscosity decreases the overall decomposition and deazatization rates for all of these cis-diazenes.While isomerization rates also decrease with increasing viscosity for most of the diazenes, that for cis-N-tert-butyl-N'-1-norbornyldiazene (1) increases.These results are interpreted in terms of deazatization via one-bond scission and an intermediate diazenyl radical, isomerization via nonradical inversion, and the possibility of isomerization via a diazenyl radical for 1.

cis-Diazenes. Pressure Effects on Their Thermal Deazatization and Isomerization Reactions

Effects of pressure on solution-phase rates of overall thermal decomposition, deazatization, and isomerization of several symmetric cis-diazenes (cis-azoalkanes) have been determined in hexane and in ethanol.Increasing pressure decreases all the rates.The large positive activation volumes for deazatization (e.g., +16 to +22 cm3/mol) have been interpreted in terms of a one-bond scission mechanism and an intermediate diazenyl radical.The smaller positive activation volumes for isomerization (e.g., +5 to +7 cm3/mol) are consistent with a nonradical inversion mechanism.Dramatic differences in rates between polar and nonpolar solvents are consistent with these mechanisms.